Cell News and Research

RSS

Exposure to TCE may increase risk of Parkinson’s

A novel study in twins found that exposure to trichloroethylene (TCE)—a hazardous organic contaminant found in soil, groundwater, and air—is significantly associated with increased risk of Parkinson’s disease.

14 Nov 2011

Next-generation drugs may prevent skin lesions in BRAF mutation-positive melanoma

Findings from preclinical studies in a skin cancer model showed that next-generation BRAF inhibitors used alone, or first-generation BRAF inhibitors used in combination with an epidermal growth factor receptor inhibitor, may have the potential to prevent drug-induced skin lesions in BRAF mutation-positive patients treated for melanoma.

14 Nov 2011

ZIOPHARM announces darinaparsin preclinical data on prostate cancer

ZIOPHARM Oncology, Inc., a drug development company employing small molecule and synthetic biology approaches to cancer therapy, announced today that results from preclinical studies of darinaparsin (Zinapar or ZIO-101), a novel organic arsenic, in prostate cancer were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place November 12-16 in San Francisco.

14 Nov 2011

Combination of REGN910 and aflibercept inhibits tumor angiogenesis in animal models

Combining the investigational agents REGN910 and aflibercept yielded statistically significant improvements in antitumor effects in animal models compared with either agent alone, according to results presented at the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, held Nov. 12-16, 2011.

14 Nov 2011

Amplification of ALK gene may drive rapid breast cancer metastasis

Amplification of anaplastic lymphoma kinase, which has been reported in other cancers such as non-small cell lung cancers, may be a primary driver of the rapid metastasis that patients with inflammatory breast cancer experience.

14 Nov 2011

Researchers show how ER-positive breast cancer tumors become resistant to tamoxifen

Researchers have shown how estrogen receptor-positive breast cancer tumors become resistant to tamoxifen, the only approved hormonal therapy for premenopausal patients with this type of breast cancer.

14 Nov 2011

Exelixis reports cabozantinib phase 2 trial data on bone metastases

Exelixis, Inc. today reported interim data on pain relief and related reduction in narcotic analgesic use with cabozantinib in castration-resistant prostate cancer (CRPC) patients with bone metastases.

14 Nov 2011

Researchers identify new cancer drug discovery approach

Researchers at the University of California, San Diego School of Medicine and the UC San Diego Moores Cancer Center have identified a new drug discovery approach enabling the destruction of the most highly proliferative tumors.

14 Nov 2011

New data on TetraLogic's TL32711 cancer drug to be presented at AACR-NCI-EORTC conference

TetraLogic Pharmaceuticals, a biopharmaceutical company developing novel small molecule Smac mimetic drugs to treat cancer, today announced presentations of new data on its Smac mimetic drug candidate TL32711 at the 2011 AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics in San Francisco.

14 Nov 2011

Patients with KRAS mutant NSCLC should respond well to antifolates

Patients with non-small cell lung cancer who have mutations in the KRAS gene should respond well to the antifolate class of drugs, according to results of a recent study conducted by Quintiles comparing human lung cancer cell lines and patients.

14 Nov 2011

Researchers retrace evolution of unusual bacterial infection

Researchers at Harvard Medical School and Children's Hospital Boston have retraced the evolution of an unusual bacterial infection as it spread among cystic fibrosis patients by sequencing scores of samples collected during the outbreak, since contained.

14 Nov 2011

New stem cell technique hopes to replace damaged cells in Parkinson's

Australian scientists have developed a new technique using stem cells, in the hope to replace damaged cells in Parkinson's disease. The technique could be developed for application in other degenerative conditions.

13 Nov 2011

Parkinson’s disease breakthrough using stem cell therapy

Australian scientists are on the brink of a discovery that could change treatment of patients with Parkinson’s disease (PD). Transplanting stem cells could be the next big thing in PD therapy they claim.

13 Nov 2011

Penn study on gut cell regeneration reconciles long-standing research controversy

The lining of the intestine regenerates itself every few days as compared to say red blood cells that turn over every four months. The cells that help to absorb food and liquid that humans consume are constantly being produced. The various cell types that do this come from stem cells that reside deep in the inner recesses of the accordion-like folds of the intestines, called villi and crypts.

11 Nov 2011

Mutations make Staph more resistant to antibiotics

Infectious diseases specialists from Austin Health are working closely with Microbiologists from the University of Melbourne to understand how Staph is becoming resistant to all antibiotic therapies.

11 Nov 2011

Cultivating cells in sealed, sterile plastic bags

Using plasmas, sealed plastic bags can be modified at atmospheric pressure so that human cells can adhere to and reproduce on their walls. Cell culture bags of this kind are an important aid for research and clinical purposes and may eventually replace the Petri dishes used today.

11 Nov 2011

NeoStem third quarter revenues increase to $17.8 million

NeoStem, Inc., an international biopharmaceutical company with a focus on cell based therapeutics development, today reported third quarter results and recent progress in its business.

11 Nov 2011

Health law alphabet soup: ACOs, MLR and other implementation news

The Centers for Medicare and Medicaid Services has released the application for its shared savings program, and Health News Florida reports which of that state's providers will likely throw their hats into the ring.

11 Nov 2011

Oncostatin M could help heal damaged heart muscle tissue

Oncostatin M regulates the reversion of heart muscle cells into precursor cells and is vitally important for the self-healing powers of the heart

11 Nov 2011

ADVENTRX prices underwritten public offering of common stock

ADVENTRX Pharmaceuticals, Inc. today announced the pricing of an underwritten public offering of 21,250,000 shares of its common stock and warrants exercisable for up to 10,625,000 additional shares at $0.80 per fixed combination of shares and warrants for gross proceeds of approximately $17 million.

11 Nov 2011